Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Mustang Bio Q3 2026 Results: Net Loss of $964K, Loss Widens

Mustang Bio, Inc. reported a net loss of $3.0 million for the nine months ended September 30, 2026, compared to $1.4 million in the prior year period. As of September 30, 2026, the company maintained $14.3 million in cash and cash equivalents and an accumulated deficit of $401.6 million, noting that additional capital will be required to fund future operations.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-1.0-0.5
EPS (diluted, $ a share)$-0.14$-0.07

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: MBIO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Mustang Bio, Inc.: key numbers

Share price
$0.3900Close, Nov 17
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Mustang Bio, Inc.

All →
4:06 PM ET 8-K
Nasdaq/NYSE Compliance Notice

Mustang Bio Nasdaq/NYSE Compliance Notice

Mustang Bio received a second 180-day grace period from Nasdaq, until April 12, 2027, to regain compliance with the $1.00 minimum bid price requirement. The company intends to monitor its stock price and may effect a reverse stock split if necessary to maintain its listing on the Nasdaq Capital Market.

Counterparty
Nasdaq
Term
180 days

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.